vaccine. However, CEO vaccines can revert to virulent ILTV and cause outbreaks. One of the successes of the recombinant vaccines with gene inserts for ILT is that they do not revert to virulence, but do prevent ILT symptoms. However, these same recombinant vaccines do not necessarily prevent replication of ILTV in the trachea of chickens, which then can lead to ILT outbreaks.
One of the regulations for ILT vaccines is that they must protect chickens against inoculation with an ILT challenge virus. All licensed vaccines in the U.S. are licensed by the United States Department of Agriculture's (USDA) Center for Veterinary Biologics (CVB). The CVB provides ILT challenge virus to biologics companies for efficacy testing of vaccines. The current USDA challenge virus strain was generated through egg passage from a 1960s strain of ILTV. Recently, the CVB was able to acquire an ILT field isolate from an outbreak in a laying hen flock that had been vaccinated with a recombinant ILT vaccine.
Mortality, clinical signs and pathogenicity of this field isolate were compared to the current USDA challenge virus. An interesting aspect of the research was that several asymptomatic chickens still had tracheal lesions, both from the field isolate and current challenge virus, indicating viral replication without clinical signs. This is not entirely surprising due to research indicating similar results with some recombinant ILT vaccines, ix but it does reinforce that prevention of symptoms does not equal prevention of viral replication.
The ILT field isolate produced clinical signs and tracheal lesions similar to the USDA challenge virus, and the field isolate was able to cause symptoms at a lower infectious douse then the USDA challenge virus to achieve the same results. These results indicate that the ILT field isolate is a viable candidate for use in vaccination challenge studies. Future work will need to be undertaken to perform genetic analysis of the ILT field strain isolated by the USDA and other field strains to determine genetic relationship to vaccine strains.
CHAPTER 1. INFECTIOUS LARYNGOTRACHEITIS AND VACCINATION

Abstract
Infectious laryngotracheitis virus (ILTV) causes respiratory distress, reduction in egg production, conjunctivitis, and death in chickens. Severe cases of infectious laryngotracheitis (ILT) can have morbidity of 100% and mortality rates as high as 70%, with the average percentage for mortality ranging from 10-20%. In mild cases, morbidity can be as low as 5% and mortality can be as low as 0.1%. In the United States, vaccination for ILT is predominately performed using one of the types of vaccines: chick embryo origin (CEO), tissue culture origin (TCO) and recombinant vaccines.
It is critical that traditional live attenuated ILT vaccines prevent disease by preventing infection by wild type strains. However, these vaccines can revert to virulence and cause outbreak situations. The recombinant vaccines prevent disease and do not revert to virulence, but they may allow wild type strains to infect and replicate in birds, which can also lead to outbreaks.
The importance of not only preventing disease, but also infection, has become more apparent as the understanding of the immunological response to ILTV and ILT vaccines has increased. Current research into different vaccination methods, new vectors for recombinant vaccines, and eliciting a cell mediated immune response in the trachea has moved ILT vaccination towards preventing infection.
ILT prevention is a complex challenge. This literature review will give an overview of the ILT virus, advantages and disadvantages associated with currently license vaccines in the U.S, and recent research to improve vaccination for ILT.
Introduction
Infectious laryngotracheitis virus (ILTV) causes respiratory distress, reduction in egg production, conjunctivitis, and death in chickens (1) . It is an alphaherpesvirus that can cause both severe and mild disease (1) (2) (3) . Severe cases of infectious laryngotracheitis (ILT) can have morbidity of 100% and mortality rates as high as 70%, with the average percentage for mortality ranging from 10-20% (3). In mild cases, morbidity can be as low as 5% and mortality can be as low as 0.1% (3) . Clinical manifestations in mild forms include conjunctivitis, whereas more severe forms may include birds coughing blood from tracheal epithelial cell hemorrhage (3, 4) .
In the United States, vaccination for ILT is predominately performed using one of the types of vaccines: chick embryo origin (CEO), tissue culture origin (TCO) and recombinant vaccines (3). This literature review will give an overview of the ILT virus, advantages and disadvantages associated with currently license vaccines in the U.S, and recent research to improve vaccination for ILT.
Infectious Laryngotracheitis Virus
2.1. Strain similarities and differences. Discerning differences in ILTV strains has traditionally been performed using restriction fragment length polymorphism (RFLP)
analysis. The RFLP analysis divides ILTV strains into different classes based on genetic markers of ILTV, including genes for ICP4, glycoprotein G, glycoprotein M, and thymidine kinase (5) (6) (7) (8) (9) (10) . Current research has also focused on full genome sequencing to discern strain differences (9, 10).
Data from both RFLP and sequencing indicates that ILTV strains are genetically similar. However, there are distinct differences between American-European strains and
Australian strains (8) (9) (10) . The Serva strain of ILTV is predominately found in vaccines and has been genetically linked to outbreak strains in Europe and the Americas. The SA2
and A20 strains are predominately found in vaccines and outbreak strains in Australia.
This difference in strains by continent has led to variations in RFLP class designation between the American and Australian ILTV strains (6) (7) (8) 10) .
Although ILTV strains are genetically similar, small genetic differences in herpesviruses can cause dramatic changes in clinical symptoms. The SA2 and A20 strains are 99.9% genetically identical. The SA2 strain is a CEO vaccine in Australia.
To reduce the virulence of the SA2 strain, the virus was passed in chicken cells. The TCO vaccine that was produced was designated the A20 strain. Based on full genomic sequencing, SA2 and A20 have two single nucleotide polymorphisms (SNP) that are nonsynonymous, one in ORF B and one in UL15 genes. Amino acid changes in these two genes appear to cause a decrease in cell to cell spread in the A20 strain, and in the process, decrease the virulence of the virus (9).
The importance of the genetic differences between the continental strains was not fully realized until a European vaccine for ILTV was introduced into Australia. Flocks in the same geographical area were vaccinated with the standard Australian strain A20 and the European Serva vaccine strain (8, 11) . Following a disease outbreak in this area, two new strains of ILTV were isolated. Based on RFLP analysis, sequencing and phylogenetic analysis, the recovered strains were genetically very similar and were a result of recombination events of the European and Australian vaccine strains. An example of one of the recombination events is that the ICP4 sequence of the Australian strain was replaced with the ICP4 from the American strain (8, 10, 11) .
Although this is the first time a significant recombination event was documented causing an outbreak of ITLV, it has happened before (10) . Based on phylogenetic analysis outbreaks in production facilities can often be traced back to vaccine strains, however outbreaks in backyard flocks can be caused by virus that is genetically different than vaccine strains. These backyard flock strains have genetic components that are similar to vaccine strains, but also have elements that are different, indicating that recombination of ILTV may happen more often than first thought (10). for ILT disease prevention is discussed more in depth later in this paper.
Recombinant vaccine regulation in the United States
As of January 2015, 31 poultry products licensed in the US included a recombinant agent (12). In the early 1990s, the first poultry recombinant vaccine was For ILT recombinant vaccines, the vaccine has to perform to the same efficacy standards as the traditional ILT vaccines. This efficacy standard is tied to a vaccination challenge study described in 9CFR 113.328 (39). The vaccination challenge study involves vaccinating 20 birds and then challenging them with a virulent ILT virus, which can be provided by the CVB. The birds are monitored for ten days for ILT disease symptoms. Protection is measured based on decrease of symptoms of the disease when compared to non-vaccinated, ILTV challenged control birds (39).
ILT recombinant vaccination problems
Protection from ILT disease by vaccination with ILT recombinant vaccines depends on a humoral immune response and antibody production to the ILTV glycoprotein inserts. However, it was determined that ILTV immunity is driven by cell As mentioned previously, upon stress, the latent virus can be reactivated and disease outbreaks can occur. 
Conclusion
Infectious laryngotracheitis is a major issue for the poultry industry. As an example, a 1998 outbreak in the Delmarva peninsula in the Eastern United States cost producers over $1 million dollars, factoring in decreased production, mortality, vaccination and medication (4) . It is also a complex issue, since vaccination can be a major factor in outbreaks. 
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Abstract
Infectious laryngotracheitis virus (ILTV) causes respiratory disease in chickens.
This alphaherpesvirus infects laryngeal tracheal epithelial cells and causes outbreaks culminating in decreases in egg production, respiratory distress in chickens and mortality. Using the challenge virus and various dilutions of the field isolate, clinical signs, mortality and pathology were evaluated in chickens. Results indicate that the field isolate at a 1:20 dilution is comparable in pathogenicity to the USDA challenge virus at a 1:4 dilution, and that the ILTV field isolate is a viable candidate that could be used as a challenge virus when evaluating vaccine efficacy.
Introduction
Infectious Laryngotracheitis (ILT) is a respiratory disease of chickens which is caused by an alphaherpesvirus and classified as Gallid herpesvirus 1. Disease manifestations include respiratory distress, conjunctivitis, and a decrease in egg production and mortality ( 
Materials and Methods
This study was conducted in accordance with the Guide for the Care and Use of Laboratory Animals and approved by the CVB and National Veterinary Services Laboratories (NVSL) Animal Care and Use Committee. Approximately 250 mL of homogenate was collected and then brought to a one liter volume using TPB with 2% penicillin-streptomycin and 1.5 mL was placed into glass cryules using a Cornwall syringe. Cryules were sealed using a heat sealer and stored at - 
Testing for extraneous agents.
Both the USDA challenge virus and the ILT field isolate were tested for poultry extraneous agents in the standard manner as master seed viruses as laid out in the 9CFR or in USDA Veterinary Services (VS) memorandum. ) of the challenge virus and field isolate were prepared in TPB and 0.2 ml was inoculated via the CAM inoculation route. Six eggs per dilution were inoculated and after seven days the CAMs were scored for typical ILT lesions. The 50% egg infectious dose (EID 50 ) was calculated using the Reed-Muench method (18) . Egg titrations were performed on both the USDA challenge virus and field isolate after bottling and freezing, with challenge virus having an EID 50 of 1 x10 4.1 and the field isolate having an EID 50 of 1 x10 3.4 .
Experimental Design. Ninety White Leghorn specific pathogen free chickens
(Charles River Laboratories, Wilmington, Massachusetts) were randomized into eight treatment groups at approximately 7 days of age and housed in separate isolator cages (PLAS Labs, East Lansing, Michigan) by treatment group (Table 1) . The negative control group and six treatment groups inoculated with the ILT field isolate contained 10 chickens. Twenty chickens were inoculated with USDA's current ILT challenge strain.
Twenty chickens were used for the USDA challenge virus to give a larger number of birds to compare to the field isolate. Each bird was given a unique leg band to allow for clinical signs and pathological tracking by bird.
Viruses were diluted in TPB, and at 34 days of age, each bird was inoculated intratracheally with 0.5 mL of appropriate inoculum based on treatment group (Table 1) .
The scientist performing chicken inoculations was unaware of the virus origin and dilution. After inoculation, the virus solutions used to make the dilutions were titrated in eggs to determine the EID 50 , with the USDA challenge having a value of 1 x 10 3.5 and field isolate having a value of 1 x 10 2.8 . From those values, the EID 50 was calculated for each treatment group for both the field isolate and USDA challenge virus (Table 3) .
Scoring of Clinical Signs.
After inoculation, birds were observed independently, twice daily, by two observers for ten days, and symptoms were scored according to criteria modified from previous work ( Table 2 ) (19) . Observers were blinded to the identity of each treatment group. Chickens demonstrating hemorrhaging or severe dyspnea were humanely euthanized, necropsied and tracheas were harvested. On day 10, the remaining birds were humanely euthanized, necropsied and tracheas 
Histological sample processing.
Transverse sections of trachea were fixed in neutral buffered formalin, processed and embedded in paraffin, sectioned to 3 µm thickness, mounted on glass slides, and stained with hematoxylin and eosin.
Histopathological scoring.
Tracheal lesions were scored using a scoring system (Table 2 ) modified from a previous work (21) . In the present study, tracheal lesions reflect lesions at the time of death, whether death occurred naturally, at the humane endpoint, or at the end of the study. Scoring criteria reflect not only the progression of acute inflammatory changes, but also takes into consideration more chronic regenerative changes seen in birds that have been known to recover from infection with the virus. Lesion severity was based on loss of mucosal integrity, so that lesions demonstrating sloughing and ulceration were given higher scores than lesions in which the mucosa was covered by a thickened, but intact, regenerating epithelium (Table   2) . A bird was considered positive with a tracheal lesion score of 2 or higher. Tracheal lesion scores of 4 or 5 were considered severe.
Results
Pathogenicity.
Clinical signs observed included conjunctivitis, mild dyspnea, severe dyspnea, and hemorrhaging from the oropharyngeal cavity and nostrils. Most signs were observed at 4-6 days post-inoculation, except for conjunctivitis, which was observed 5-10 days post-inoculation. Several birds from virus inoculated groups were able to recover from dyspnea, depression and conjunctivitis.
Death or euthanasia due to severe symptoms occurred in most chickens at 4 to 5 days post-inoculation. This is similar to results previously reported by researchers using other strains of ILTV (19, 21) . The present USDA challenge virus had a mortality rate of 35%. Similar mortality rates were seen for the field isolate at dilutions of 1:4, 1:20, and 1:50, which produced mortality rates of 30%, 40%, and 30%, respectively.
Tracheal Lesion Scores.
Control birds had normal to slightly hyperplastic tracheal mucosa (Fig. 1a) . Infected birds demonstrated a variety of lesions ranging from slightly hyperplastic through epithelial syncytia formation and sloughing to complete ulceration with a hemorrhagic and cellular exudate (Fig. 1b-1f) . Occasional birds had intact, occasionally cystic, thickened epithelium interpreted as regeneration (Fig. 1d ).
Upper and lower tracheal lesion scores for each experiment chicken, the percentage of birds in each group with positive lesions and the percentage of birds in each group with severe lesions is summarized in Table 4 . The USDA challenge virus at a ILT prevention is an important, but complex problem for the poultry industry.
Live, attenuated vaccines can revert to virulence (4-6). Through normal farm procedures, chickens shedding live vaccine can infect naïve chickens (7). Recombinant vaccines expressing one or two glycoproteins of ILTV in a herpesvirus of turkeys or fowl pox vector do not revert to virulence, but allow wild type virus to infect, which can lead to outbreaks at a later date (8, 9) .
Traditional CEO ILT vaccines are often composed of genetic subpopulations known as quasispecies (10) . This is important in relation to the USDA ILT challenge virus which derived from a vaccine strain and has been maintained by passage in eggs.
The USDA ILT challenge virus used to test vaccine efficacy was recently found to have become attenuated, requiring increased inoculation concentration to achieve virulence Outside of biosecurity measures, vaccination is the most used control measure for ILT prevention, yet itself is a contributing factor in the epidemiology of the disease.
Control of ILT in poultry flocks will require increased understanding of ILTV biology and poultry immunology. A better way to control the complex problem of ILT is possible, but it will involve a multi-faceted approach of incorporating research across the herpesvirus family, educating producers, investigating new technologies, and working with biologics producers and regulators.
